CSIMarket
 
Candel Therapeutics Inc   (CADL)
Other Ticker:  
 
 
Price: $6.6600 $-0.62 -8.516%
Day's High: $7.5 Week Perf: 3.58 %
Day's Low: $ 6.57 30 Day Perf: 296.43 %
Volume (M): 6,817 52 Wk High: $ 7.92
Volume (M$): $ 45,403 52 Wk Avg: $1.39
Open: $6.85 52 Wk Low: $0.66



 Market Capitalization (Millions $) 193
 Shares Outstanding (Millions) 29
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 1

Candel Therapeutics Inc
Candel Therapeutics Inc is a clinical-stage biotechnology company that focuses on the development of novel oncolytic viral immunotherapies for the treatment of certain types of cancer. Using their proprietary CANDEL platform, the company engineers viruses to selectively target and destroy cancer cells while activating the immune system to mount an anti-tumor response. Their goal is to develop safe and effective treatments that can improve patient outcomes and potentially provide long-term remission in various cancers.


   Company Address: 117 Kendrick St Needham 2494 MA
   Company Phone Number: 916-5445   Stock Exchange / Ticker: NASDAQ CADL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Candel Therapeutics Pioneers Groundbreaking Immunotherapies for Pancreatic and Brain Cancer Treatment

Published Thu, Apr 11 2024 1:01 PM UTC

Candel Therapeutics, a clinical-stage biopharmaceutical company focused on the development of innovative multimodal biological immunotherapies, has achieved significant milestones in the treatment of pancreatic and brain cancers. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Candel's most advanced candidate, CAN-2409, for pancrea...

Clinical Study

Candel Therapeutics Presents Breakthrough Data on Novel Immunotherapy Candidate and Updates on Clinical Trials

Published Tue, Apr 9 2024 12:00 PM UTC

Candel Therapeutics, a clinical-stage biopharmaceutical firm with a strong emphasis on the development of multimodal biological immunotherapies for cancer patients, recently unveiled preclinical data at the AACR Annual Meeting in San Diego. The information revolved around an innovative first-in-class multimodal immunotherapy candidate aimed at inducing tertiary lymphoid stru...

Clinical Study

Revolutionizing Pancreatic Cancer Treatment: The Pivotal Role of Candel?s CAN-2409

Published Thu, Apr 4 2024 12:01 PM UTC

In an ongoing stride towards innovative cancer treatments, Candel Therapeutics, Inc. - a clinical stage biopharmaceutical firm committed to developing multimodal biological immunotherapies to counter cancer, recently shared promising interim survival data from their ongoing randomized phase 2 clinical trial of the complex CAN-2409 therapy employed to treat non-metastatic pan...

Clinical Study

Promising Update on the Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Published Thu, Mar 28 2024 8:05 PM UTC

Candel Therapeutics, a clinical stage biopharmaceutical company, recently presented updated data from an ongoing phase 1b clinical trial of their viral immunotherapy candidate, CAN-3110, during the 5th Glioblastoma Drug Development Summit in Boston, Massachusetts. This article aims to ly outline the key facts and implications of the presentation, shedding light on the potent...

Product Service News

Candel Therapeutics on Track for Success: Recent Accomplishments Lay the Foundation for a Promising 2024

Published Mon, Feb 5 2024 1:00 PM UTC

Candel Therapeutics, a renowned biotechnology company, has been making significant strides in recent times, propelling itself towards a highly promising future in 2024. With a focus on key value drivers and effective catalysts, the company has achieved noteworthy benchmarks that demand attention. This article aims to outline the prominent achievements of Candel Therapeutics ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com